Q4 2024 Allogene Therapeutics Inc Earnings Call Transcript

Mar 13, 2025 / 09:00PM GMT

Release Date Price: $1.89 (-8.25%)

Transcript 10-K8-K

Key Points

Positve

Allogene Therapeutics Inc (ALLO) is approaching critical milestones in its key programs, including large B-cell lymphoma, autoimmune disease, and renal cell carcinoma.
The pivotal Phase 2 ALPHA3 trial for cema-cel in large B-cell lymphoma is considered groundbreaking, with 40 sites activated and a critical milestone expected by mid-2025.
ALLO-329, a dual-targeting allogeneic CAR T product candidate for autoimmune diseases, has received FDA clearance for a Phase 1 trial, showcasing innovation in the field.
ALLO-316 shows promise in renal cell carcinoma, with encouraging Phase 1 data and a potential to redefine treatment for advanced cases.
The company maintains a strong financial position with $373.1 million in cash and a cash runway extending into the second half of 2026.

Negative

The company reported a net loss of $257.6 million for the full year of 2024, highlighting ongoing financial challenges.
There is uncertainty regarding the need for lymphodepletion in the ALPHA3 trial, which could impact the trial's outcome and future strategy.
The competitive landscape in the CAR T space, particularly in autoimmune diseases, poses challenges for differentiation and market positioning.
The success of the ALLO-329 program is contingent on achieving biomarker-based proof-of-concept, which carries inherent risks.
The timeline for achieving significant clinical outcomes, such as durable efficacy in the ALLO-329 trial, remains uncertain and could affect investor confidence.

Operator

Hello. Thank you for standing by, and welcome to Allogene Therapeutics Fourth Quarter and Full Year 2024 Conference Call. (Operator Instructions) Please be aware that today's conference call is being recorded. I would like to turn the call over to Christine Cassiano, Chief Corporate Affairs and Brand Strategy Officer. Ms. Cassiano, please go ahead.

Christine Cassiano

Allogene Therapeutics Inc - Executive Vice President, Chief Corporate Affairs and Brand Strategy Officer

Thank you, operator, and thanks to all of you for joining this call. After the market closed, Allogene issued a press release that provided a business update and financial results for the fourth quarter and full year of 2024. This press release and today's webcast are available on our website. Following our prepared remarks, we will host a Q&A session. We recognize that historically, questions have been multifaceted, but note that we will endeavor to keep this call to under an hour. I'm joined today by Dr. David Chang, President and Chief Executive Officer; Dr. Zachary Roberts, Executive

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.